Family

Differences between Psychotic Disorders with Concurrent Cannabis Use and Cannabis-Induced Psychoses

Scientific article

6 February 2017

Abstract Background: The fact that Cannabis use can lead to psychotic symptoms has been recognized years ago. Moreover, when the patient is using cannabis, the distinction between a primary psychotic disorder and a cannabis-induced...

Heroin Uncertainties: Exploring Users’ Perceptions of Fentanyl-Adulterated and -Substituted ‘Heroin’

Scientific article

17 July 2017

Abstract Background The US is experiencing an unprecedented opioid overdose epidemic fostered in recent years by regional contamination of the heroin supply with the fentanyl family of synthetic opioids. Since 2011 opioid-related overdose...

Tobacco Use Decreases Visual Sensitivity in Schizophrenia

Scientific article

6 March 2018

Smoking prevalence in patients who are diagnosed with schizophrenia (SCZ) is higher than in the general population. Chronic tobacco use in SCZ patients may reduce the side effects of antipsychotic drugs, thus serving as a self-medication...

Stressful Experiences Affect Likelihood of Remission of Drug Dependence, Continued Drug Use, and Relapse

Scientific article

15 August 2015

Researchers at the University of Michigan’s Centre for the Study of Drugs, Alcohol, Smoking and Health have been exploring the link between drug dependence, ongoing drug use, relapse and exposure to stress or experience of stressful events...

NIDA Scientists Review Impact of Smoking among Adolescents with ADHD

Scientific article

Two studies funded by NIDA have highlighted a correlation between ADHD symptoms and initial smoking age.

New from SAMHSA: Medications for Opioid Use Disorders

Book

12 February 2018

SAMHSA has released a new publication as part of the Treatment Improvement Protocol series.

Intervention guide mhGAP for mental, neurological disorders and substance use in the level of non-specialized health care. Version 2.0

Book

5 July 2017

Mental, neurological and substance (MNS) disorders are very common and represent a large burden of disease and disability around the world. There remains a wide gap between the capacity of health systems and resources, between what is...

mhGAP Intervention Guide - Version 2.0 for Mental, Neurological and Substance Use Disorders in Non-Specialized Health Settings

Book

Overview This is the second version (2016) of the mhGAP Intervention Guide (mhGAP-IG) for mental, neurological and substance use (MNS) disorders in non-specialist health settings. It is for use by doctors, nurses, other health workers as...

Certification of Addiction Professionals in Africa: An Overview of the Process in Kenya

Scientific article

28 July 2015

Abstract This paper focuses on Kenya’s course of action to address the drug problem, specifically, treatment and rehabilitation of persons with Substance Use Disorders (SUDs). Treatment and rehabilitation of persons with SUDs was formally...

Alcohol and Drugs Prevention, Treatment and Recovery: Why Invest?

Book

12 February 2018

Estimates show that in the UK the social and economic costs of alcohol related harm amount to £21.5bn, while harm from illicit drug use costs £10.7bn. These include costs associated with deaths, the NHS, crime and, in the case of alcohol...